SEC Comment Letter 0000000000-24-014329 to Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Date: Dec. 30, 2024 · CIK: 0001610618 · Accession: 0000000000-24-014329
AI Filing Summary & Sentiment
File numbers found in text: 333-284022
Letter
December 30, 2024 Jeffrey Stein President and Chief Executive Officer Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, CA 92121 Re:Cidara Therapeutics, Inc. Registration Statement on Form S-1 Filed December 23, 2024 File No. 333-284022 Dear Jeffrey Stein: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Charles J. Bair, Esq.
Show Raw Text
December 30, 2024
Jeffrey Stein
President and Chief Executive Officer
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, CA 92121
Re:Cidara Therapeutics, Inc.
Registration Statement on Form S-1
Filed December 23, 2024
File No. 333-284022
Dear Jeffrey Stein:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Charles J. Bair, Esq.